pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,762 catalysts · 4,686 phase readout · 2,347 8k filing · 285 earnings · 201 pdufa · 172 phase 2 completion · 73 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 14 catalysts2026-07-23: 2 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout4,686
  • 8k filing2,347
  • earnings285
  • pdufa201
  • phase 2 completion172
  • phase 1 completion73
  • phase 2 initiation62
  • phase 1 initiation40
  • phase 1 2 completion35
  • phase 0 trial completion23
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 27, 2026

    50
    ›Apr 28, 20268k filing86d ago$VTGN — Vistagen Therapeutics, Inc. (VTGN) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d ago$LABT — Lakewood-Amedex Biotherapeutics Inc. (LABT) — 8-K filing

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d agoSeaStar Medical Holding Corp (ICU, ICUCW) — 8-K filing

    Items: 8.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d ago$FLNA — FILANA THERAPEUTICS, INC. (FLNA) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d ago$PTCT — PTC THERAPEUTICS, INC. (PTCT) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d ago$HRGN — Harvard Apparatus Regenerative Technology, Inc. (HRGN) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d ago$MDGL — MADRIGAL PHARMACEUTICALS, INC. (MDGL) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d ago$FENC — FENNEC PHARMACEUTICALS INC. (FENC) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d ago$QNCX — Quince Therapeutics, Inc. (QNCX) — 8-K filing

    Items: 8.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d ago$PREM — Premier Air Charter Holdings Inc. (PREM) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d agoScilex Holding Co (SCLX, SCLXW) — 8-K filing

    Items: 1.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d ago$JANX — Janux Therapeutics, Inc. (JANX) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d ago$CTOR — CITIUS ONCOLOGY, INC. (CTOR) — 8-K filing

    Items: 3.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d ago$QUCY — Quantum Cyber N.V. (QUCY) — 8-K filing

    Items: 1.01, 3.02, 5.01, 5.02, 5.03, 5.07, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d ago$GRDX — GridAI Technologies Corp. (GRDX) — 8-K filing

    Items: 3.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing86d ago$LNAI — Lunai Bioworks Inc. (LNAI) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 2026pdufa85d agoSanofi — teplizumab (PDUFA)teplizumab

    Therapy area: Metabolic Disorders. Indication: Type 1 Diabetes (Juvenile Diabetes)

    full page →teplizumab →source: globaldata
    ›Apr 29, 2026phase 0 trial completion85d agoDana-Farber Cancer Institute Inc — atezolizumab (Phase 0 Trial Completion)atezolizumab

    Therapy area: Oncology. Indication: Hepatocellular Carcinoma, Liver Cancer

    full page →atezolizumab →source: globaldata
    ›Apr 29, 2026phase 1 completion85d agoBoehringer Ingelheim International GmbH — BI-765179 (Phase I Trial Completion)BI-765179

    Therapy area: Oncology. Indication: Cervical Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer, Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hepatocellular Carcinoma, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Pleural Mesothelioma, Melanoma, Non-Small Cell Lung Carcinoma, Oral Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Re

    full page →BI-765179 →source: globaldata
    ›Apr 29, 2026phase 1 completion85d agoUniversity of Washington — autologous mitochondria (Phase I Trial Completion)autologous mitochondria

    Therapy area: Cardiovascular. Indication: Cerebrovascular Disease, Ischemia

    full page →autologous mitochondria →source: globaldata
    ›Apr 29, 2026phase 1 completion85d agoAltasciences Co Inc — NN-7442 (Phase I Trial Completion)NN-7442

    Therapy area: Hematological Disorders. Indication: Hemophilia A (Factor VIII Deficiency)

    full page →NN-7442 →source: globaldata
    ›Apr 29, 2026phase 1 initiation85d agoTerSera Therapeutics LLC — goserelin LA (Phase I Trial Initiation)goserelin LA

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

    full page →goserelin LA →source: globaldata
    ›Apr 29, 2026phase 1 initiation85d agoOcugen Inc — adenovirus vector (spike protein) vaccine (Phase I Trial Initiation)adenovirus vector (spike protein) vaccine

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19)

    full page →adenovirus vector (spike protein) vaccine →source: globaldata
    ›Apr 29, 2026phase 1 initiation85d agoAgios Pharmaceuticals Inc — AG-181 (Phase I Trial Initiation)AG-181

    Therapy area: Metabolic Disorders. Indication: Phenylketonuria (PKU)

    full page →AG-181 →source: globaldata
    ›Apr 29, 2026phase 1 initiation85d agoBayer AG — asundexian (Phase I Trial Initiation)asundexian

    Therapy area: Cardiovascular. Indication: Ischemic Stroke

    full page →asundexian →source: globaldata
    ›Apr 29, 2026phase 2 completion85d agoCARsgen Therapeutics Holdings Ltd — CT-0594CP CAR-T Cells (Phase II Trial Completion)CT-0594CP CAR-T Cells

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Plasma Cell Neoplasm, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →CT-0594CP CAR-T Cells →source: globaldata
    ›Apr 29, 2026phase 2 completion85d agoTexas Christian University — Alii Supplement (Phase II Trial Completion)Alii Supplement

    Therapy area: Nutritional Disorders. Indication: Unspecified Nutritional Disorders

    full page →Alii Supplement →source: globaldata
    ›Apr 29, 2026phase 2 completion85d agoMassachusetts Eye and Ear Infirmary — N-acetylcysteine (Phase II Trial Completion)N-acetylcysteine

    Therapy area: Ophthalmology. Indication: Cataract, Fuchs Endothelial Corneal Dystrophy (FECD)

    full page →N-acetylcysteine →source: globaldata
    ›Apr 29, 2026phase 2 completion85d agoNational Heart Lung and Blood Institute — danazol (Phase II Trial Completion)danazol

    Therapy area: Gastrointestinal, Genetic Disorders, Hematological Disorders, Respiratory. Indication: Cytopenia, Liver Fibrosis, Mutational Disorders, Pulmonary Fibrosis

    full page →danazol →source: globaldata
    ›Apr 29, 2026phase 2 completion85d agoSaraswati Dhanwantari Dental College and Hospital Parbhani — (amoxicillin + clavulanic acid) (Phase II Trial Completion)(amoxicillin + clavulanic acid)

    Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Periodontitis, Unspecified Infectious Diseases

    full page →(amoxicillin + clavulanic acid) →source: globaldata
    ›Apr 29, 2026phase 2 completion85d agoBangalore Medical College and Research Institute — dinoprostone (Phase II Trial Completion)dinoprostone ER

    Therapy area: Dermatology. Indication: Vitiligo

    full page →dinoprostone ER →source: globaldata
    ›Apr 29, 2026phase 2 completion85d agoNational Institute of Unani Medicine — unani medicine (Phase II Trial Completion)unani medicine

    Therapy area: Women's Health. Indication: Menorrhagia

    full page →unani medicine →source: globaldata
    ›Apr 29, 2026phase 2 initiation85d agoNefro Avillion Clinical Development LLC — siplizumab (Phase II Trial Initiation)siplizumab

    Therapy area: Immunology. Indication: Kidney Transplant Rejection

    full page →siplizumab →source: globaldata
    ›Apr 29, 2026phase 2 initiation85d agoSawai Man Singh Medical College — phenylephrine (Phase II Trial Initiation)phenylephrine

    Therapy area: Cardiovascular. Indication: Hypotension

    full page →phenylephrine →source: globaldata
    ›Apr 29, 2026phase 2 initiation85d agoKyowa Kirin Co Ltd — KK-4277 (Phase II Trial Initiation)KK-4277

    Therapy area: Immunology. Indication: Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus

    full page →KK-4277 →source: globaldata
    ›Apr 29, 2026phase 2 initiation85d agoYunpeng Pharmaceutical Co Ltd — norfloxacin (Phase II Trial Initiation)norfloxacin

    Therapy area: Gastrointestinal, Genito Urinary System, Infectious Disease. Indication: Gonorrhea, Intestinal Infection, Salmonella Infections, Typhoid Fever, Urinary Tract Infections

    full page →norfloxacin →source: globaldata
    ›Apr 29, 2026phase 2 initiation85d agoGovernment Medical College and Hospital Chandigarh — bupivacaine (Phase II Trial Initiation)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 29, 2026phase 2 initiation85d agoNational Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)(daratumumab + hyaluronidase (human recombinant))

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma

    full page →(daratumumab + hyaluronidase (human recombinant)) →source: globaldata
    ›Apr 29, 2026phase 2 initiation85d agoGoa Medical College — diclofenac (Phase II Trial Initiation)diclofenac ER

    Therapy area: Oncology, Toxicology. Indication: Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome), Colon Tumor

    full page →diclofenac ER →source: globaldata
    ›Apr 29, 2026phase 2 initiation85d agoShenzhen Resproly Biopharmaceutical Co Ltd — RSN-0402 (Phase II Trial Initiation)RSN-0402

    Therapy area: Respiratory. Indication: Idiopathic Pulmonary Fibrosis, Interstitial Lung Fibrosis

    full page →RSN-0402 →source: globaldata
    ›Apr 29, 2026phase 2 initiation85d agoHuahui Health Ltd — HH-006 (Phase II Trial Initiation)HH-006

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →HH-006 →source: globaldata
    ›Apr 29, 2026phase 2 results85d agoSt. Vincent Health System — [177Lu]Lu-PSMA-597 (Phase II Trial Results)[177Lu]Lu-PSMA-597

    Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Prostate Cancer, Prostate Cancer

    full page →[177Lu]Lu-PSMA-597 →source: globaldata
    ›Apr 29, 2026phase 2 3 completion85d agoFaculty of Medicine Chulalongkorn University — melatonin ER (Phase II/III Trial Completion)melatonin ER

    Therapy area: Gastrointestinal. Indication: Irritable Bowel Syndrome

    full page →melatonin ER →source: globaldata
    ›Apr 29, 2026phase 2 3 initiation85d agoPacific Dental College and Hospital — nicotine (Phase II/III Trial Initiation)nicotine

    Therapy area: Central Nervous System. Indication: Addictive Disorders, Smoking Cessation

    full page →nicotine →source: globaldata
    ›Apr 29, 2026phase 3 completion85d agoBuddhachinaraj Hospital — nefopam (Phase III Trial Completion)nefopam

    Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Osteoarthritis, Post-Operative Pain

    full page →nefopam →source: globaldata
    ›Apr 29, 2026phase 3 completion85d agoAstraZeneca Plc — durvalumab (Phase III Trial Completion)durvalumab

    Therapy area: Genito Urinary System, Oncology. Indication: Bladder Cancer, Bladder Carcinoma, Kidney Cancer (Renal Cell Cancer), Metastatic Transitional (Urothelial) Tract Cancer, Renal Stones/Calculi, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer

    full page →durvalumab →source: globaldata
    ›Apr 29, 2026phase 3 initiation85d agoIncyte Corp — retifanlimab (Phase III Trial Initiation)retifanlimab

    Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hypopharyngeal Cancer, Laryngeal Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Recurrent Head And Neck Squamous Cell Carcinoma

    full page →retifanlimab →source: globaldata
    ›Apr 29, 2026phase 3 initiation85d agoInstitute of Hematology and Blood Diseases Hospital — venetoclax (Phase III Trial Initiation)venetoclax

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

    full page →venetoclax →source: globaldata
    ›Apr 29, 2026phase 3 initiation85d agoChia Tai Tianqing Pharmaceutical Group Co Ltd — TQH-2722 (Phase III Trial Initiation)TQH-2722

    Therapy area: Respiratory. Indication: Seasonal Allergic Rhinitis

    full page →TQH-2722 →source: globaldata
    ›Apr 29, 2026phase 3 initiation85d agoAll India Institute of Medical Sciences Bathinda — mitomycin (Phase III Trial Initiation)Jelmyto

    Therapy area: Ophthalmology. Indication: Open-Angle Glaucoma

    full page →Jelmyto →source: globaldata
    ← prev
    page 8 of 156
    next →
    $OCGN1.3000-2.26%
    $AZN169.34+2.93%
    $AGIO37.36-6.74%
    $SNY44.12+0.85%
    $INCY117.39+1.50%